<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89130">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02028052</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00036432</org_study_id>
    <nct_id>NCT02028052</nct_id>
  </id_info>
  <brief_title>Procedural Outcomes in Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) With and Without Rapid On-Site Evaluation (ROSE)</brief_title>
  <acronym>ROSE</acronym>
  <official_title>Procedural Outcomes in Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) With and Without Rapid On-Site Evaluation (ROSE) by Cytopathologist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is comparing the attributable procedural time of Endobronchial
      Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) when sampling mediastinal and
      hilar lymph nodes with or without Rapid On-Site Evaluation (ROSE). The primary outcome will
      be the time elapsed from EBUS bronchoscope insertion to bronchoscope withdrawal. Secondary
      outcomes will include total number of sampled lymph nodes, average number of needle
      aspirations per lymph node sampled, overall diagnostic yield, and procedural time of the
      cytopathologist.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Time lapse</measure>
    <time_frame>during procedure, approximately 45 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary endpoint is the time elapsed from EBUS bronchoscope insertion to bronchoscope withdrawal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of sampled lymph nodes</measure>
    <time_frame>approximately 45 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Samples taken during procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average number of needle aspirations per lymph node sampled</measure>
    <time_frame>approximately 45 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determined by tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall diagnostic yield</measure>
    <time_frame>approximately 45 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural time of the cytopathologist</measure>
    <time_frame>approximately 30 minutes</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>ENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION</condition>
  <condition>Benign and Malignant Mediastinal and Hilar Lymph Nodes Known or Suspected Malignancy</condition>
  <arm_group>
    <arm_group_label>ROSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO ROSE</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ROSE</intervention_name>
    <description>The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.</description>
    <arm_group_label>ROSE</arm_group_label>
    <arm_group_label>NO ROSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>22 gauge Vizishot needles</intervention_name>
    <arm_group_label>ROSE</arm_group_label>
    <arm_group_label>NO ROSE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject provides informed consent

          2. Subject is &gt;18 years of age

          3. Subject is scheduled to undergo flexible bronchoscopy with EBUS-TBNA of suspected
             enlarged mediastinal or hilar  lymph nodes as part of their standard medical care

          4. A negative pregnancy test in women of child-bearing potential

          5. Subject is mentally capable of following study directions

        Exclusion Criteria:

          1. Study subject has any disease or condition that interferes with safe completion of
             initial or follow-up assessments

          2. Concurrent participation in another study involving investigational drugs or
             investigational medical devices

          3. Inability to read and understand the necessary study documents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Momen Wahidi, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yasufuku K, Chiyo M, Sekine Y, Chhajed PN, Shibuya K, Iizasa T, Fujisawa T. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest. 2004 Jul;126(1):122-8.</citation>
    <PMID>15249452</PMID>
  </reference>
  <reference>
    <citation>Mejia CP. [Surgery and orthodontics in the treatment of unerupted maxillary cuspids]. Rev Fed Odontol Colomb. 1976 Jan-Jun;24(116-117):47-52. Spanish.</citation>
    <PMID>1076725</PMID>
  </reference>
  <reference>
    <citation>Griffin AC, Schwartz LE, Baloch ZW. Utility of on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspiration specimens. Cytojournal. 2011;8:20. doi: 10.4103/1742-6413.90081. Epub 2011 Nov 21.</citation>
    <PMID>22145008</PMID>
  </reference>
  <reference>
    <citation>Layfield LJ, Bentz JS, Gopez EV. Immediate on-site interpretation of fine-needle aspiration smears: a cost and compensation analysis. Cancer. 2001 Oct 25;93(5):319-22.</citation>
    <PMID>11668466</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>December 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>enlarged mediastinal nodes</keyword>
  <keyword>enlarged hilar lymph nodes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
